New drug shows promise for Hard-to-Treat cancers in early trial

NCT ID NCT03944499

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times

Summary

This early-phase study tested a new drug called FS1502 in 161 adults with advanced solid tumors that express HER2, including HER2+ breast cancer. The goal was to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants had already tried other treatments without success. The study is complete, but results are not yet public.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, 100021, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jilin Cancer Hospital

    Jilin, Changchun, China

  • Meizhou People's Hospital

    Meizhou, Guangdong, China

  • Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University

    Hangzhou, Zhejiang, 310016, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences

    Shenzhen, Guangdong, 518000, China

  • Sun Yat-sen University Cancer Prevention Center

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050011, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Conditions

Explore the condition pages connected to this study.